Skip to content

Social and Economic Outcomes of HIV/AIDS Care and Treatment in HIV Infected South African Adults

Economic Outcomes of HIV/AIDS Care and Treatment in South Africa

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00270764
Enrollment
1065
Registered
2005-12-28
Start date
2005-07-31
Completion date
2013-09-30
Last updated
2013-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections

Keywords

HIV/AIDS, Antiretroviral therapy, Quality of life, South Africa, Treatment Naive

Brief summary

The purpose of this study is to determine the social and economic outcomes of anti-HIV treatment in South African adults, with data collected from interviews, detailed questionnaires, and patients' medical records.

Detailed description

The Government of the Republic of South Africa is implementing a national program to provide antiretroviral therapy (ART) to all eligible HIV infected South African adults. While the medical effectiveness of ART in suppressing viral replication is well established, little is known about the economic effectiveness of treatment. In particular, it is not known if treatment will offset the impact of HIV/AIDS on labor productivity, household stability, quality of life, and other aspects of social and economic development. The purpose of this study is to estimate the impact of ART on the productivity, economic welfare, and quality of life of adult HIV infected patients in South Africa. The study will investigate: * the degree of functional impairment among patients seeking care for HIV/AIDS, * the impact of treatment on the ability of patients to perform normal daily activities and attend work, * the full economic costs to patients of obtaining treatment, * the impact of treatment on sources of household income, * social and economic correlates of adherence to therapy, and * the cost of delivering ART to different types of patients in diverse settings. The study will last 4 years and will comprise a one-year cross-sectional analysis and a three-year longitudinal analysis. Data will be collected from questionnaires administered during patients' routine visits to public and non-governmental organization-based HIV clinics in South Africa. In accordance with current South African national treatment guidelines, patients who have started ART will visit a clinic every 3 months during the longitudinal analysis for a total of 12 visits; patients not yet on ART will visit a clinic every 6 months for a total of 6 visits. Questionnaire responses will be matched to indicators of disease progression and treatment history drawn from patients' medical records. The initial one-year analysis will compare outcomes for groups of patients stratified by disease stage and treatment duration. Longitudinal analysis will compare outcomes before and after the initiation of ART; each participant's responses and medical outcomes will be compared with his or her own previous results and with those of other participants at a similar stage of disease progression or treatment duration. This study will generate information needed to sustain large-scale treatment interventions, improve the focus and management of treatment delivery programs, and provide a better understanding of barriers to treatment adherence among HIV infected South African patients.

Interventions

None listed

Sponsors

United States Agency for International Development (USAID)
CollaboratorFED
National Institute of Allergy and Infectious Diseases (NIAID)
Lead SponsorNIH

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* HIV infected * Willing to accept ART if medically eligible according to South Africa's national treatment guidelines

Exclusion criteria

* Inability to answer questions due to disability * On ART for more than 6 months at the time of study entry * Refuse to accept ART despite medical eligibility

Design outcomes

Primary

MeasureTime frame
Ability to perform normal activities in previous weekPrevious week

Countries

South Africa

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026